<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Tumors of female reproductive system</journal-id><journal-title-group><journal-title xml:lang="en">Tumors of female reproductive system</journal-title><trans-title-group xml:lang="ru"><trans-title>Опухоли женской репродуктивной системы</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1994-4098</issn><issn publication-format="electronic">1999-8627</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">423</article-id><article-id pub-id-type="doi">10.17650/1994-4098-2015-1-61-68</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>MAMMOLOGY. DIAGNOSIS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>МАММОЛОГИЯ. ДИАГНОСТИКА</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">ANALYSIS OF APOPTOSIS FACTORS IN PATIENTS WITH PREINVASIVE AND INVASIVE CERVICAL CANCER</article-title><trans-title-group xml:lang="ru"><trans-title>ИССЛЕДОВАНИЕ ПОКАЗАТЕЛЕЙ АПОПТОЗА У БОЛЬНЫХ С ПРЕИНВАЗИВНЫМ И ИНВАЗИВНЫМ РАКОМ ШЕЙКИ МАТКИ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kovchur</surname><given-names>P. I.</given-names></name><name xml:lang="ru"><surname>Ковчур</surname><given-names>П. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>pkovchur@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Bachidze</surname><given-names>E. V.</given-names></name><name xml:lang="ru"><surname>Бахидзе</surname><given-names>Е. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff3"/><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kurmyshkina</surname><given-names>O. V.</given-names></name><name xml:lang="ru"><surname>Курмышкина</surname><given-names>О. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Volkova</surname><given-names>T. O.</given-names></name><name xml:lang="ru"><surname>Волкова</surname><given-names>Т. О.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Petrozavodsk State University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВПО «Петрозаводский государственный университет»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">33 Lenina prospekt, Petrozavodsk, 185910, Russia</institution></aff><aff><institution xml:lang="ru">Россия, 185910, Петрозаводск, проспект Ленина, 33</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">N.N. Petrov Oncology Research Institute, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Научно-исследовательский институт онкологии им. Н.Н. Петрова» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">68 Leningradskaya St., Pesochny, Saint Petersburg, 197758, Russia</institution></aff><aff><institution xml:lang="ru">Россия, 197758, Санкт-Петербург, пос. Песочный, ул. Ленинградская, 68</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2015-04-29" publication-format="electronic"><day>29</day><month>04</month><year>2015</year></pub-date><volume>11</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>61</fpage><lpage>68</lpage><history><date date-type="received" iso-8601-date="2015-04-30"><day>30</day><month>04</month><year>2015</year></date><date date-type="accepted" iso-8601-date="2015-04-30"><day>30</day><month>04</month><year>2015</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://ojrs.abvpress.ru/ojrs/article/view/423">https://ojrs.abvpress.ru/ojrs/article/view/423</self-uri><abstract xml:lang="en"><p><italic>This article assesses the disturbance degree of apoptotic program in patients with preinvasive and invasive cervical cancer by investigating the expression level of genes of caspases-3, -6, -8 и -9 in mononuclear cells of periphery blood and in tumor tissue on the two regulating levels – on mRNA level (transcriptional) and proteolytic activity (post transcriptional). 75 patients with stage III of cervical intraepithelial neoplasias (CIN) III  (middle age of 32,9 ± 7,4),45 patients with stage IA (31,3 ± 6,0), 21 – with stage II (43,6 ± 13,2), 15 – with stage III–IV (46,9 ± 11,1) have been examined. The control group has been formed from 30 almost healthy donors without any cervical pathology and papilloma human virus (control 1) and 30 patients with a preinvasive and microinvasive cervical cancer (control 2). It has been found that in proportion of progress of cervix cancer, the membranous expression of CD95 increases in MPB – fraction (peripheral blood monocytes) when the a CIN and initial stages of cervix cancer, more than two times. Herewith number CD95+-lymphocytes is positively correlated with stage of cervical cancer (r = 0,91; R</italic><italic>2  </italic><italic>= 0,82; p &lt;&lt; 0,01). It has been found out that the activity gain of caspase-8 (r = 0,92; R</italic><italic>2  </italic><italic>= 0,86; p &lt;&lt; 0,01), caspase-6 (r = 0,77; R</italic><italic>2 </italic><italic>= 0,59; p &lt;&lt; 0,01) and reduction activity of caspase-9 (r = –0,60;  R</italic><italic>2 </italic><italic>= 0,36; p &lt; 0,01) in mononuclear cells of peripheral blood pointed out on the sensitivity increase to Fas-induced apoptosis. Opposite, in tumor tissue, beginning from CIN stage III, apoptosis-resistant phenotype is formed, it were defined by the expression of caspase-3 (r = –0,72; R</italic><italic>2 </italic><italic>= 0,52, p &lt; 0,01), caspase-6 (r = –0,59; R</italic><italic>2 </italic><italic>= 0, 38; p &lt; 0,01) и caspase-9 (r = –0,67; R</italic><italic>2 </italic><italic>= 0,45; p &lt; 0,01) by mRNA level and proteolytic activity. It has been shown, that the cervical cancer development is accompanied by multilateral disturbances of apoptotic processes, which are realized in decreased function of caspases and multilateral resistance of tumor cells in against signals of apoptosis. The obtained results give an opportunity to examine the genes of caspase as a probable prospective biomarkers in complex diagnostic of a CIN and early diagnosis of a cervical cancer (in combination with morphological criteria and other molecular markers of viral origin)</italic></p></abstract><trans-abstract xml:lang="ru"><p><italic>В статье дана оценка степени нарушения апоптотической программы у больных преинвазивным и инвазивным раком шейки матки</italic></p><p><italic>(РШМ</italic><italic>) с помощью определения экспрессии генов каспаз-3, -6, -8 и -9 в мононуклеарах периферической крови (МНПК) и опухолевой ткани на двух уровнях регуляции – мРНК (транскрипционный уровень) и протеолитической активности (посттрансляционный уровень). Обследованы 75 больных с цервикальными интраэпителиальными неоплазиями (ЦИН) </italic><italic>II</italic><italic>I</italic><italic> </italic><italic>степен</italic><italic>и тяжести (средний возраст 32,9 ± 7,4 года), 45 – с </italic><italic>I</italic><italic>А стадией (31,3 ± 6,0 года), 21 – со </italic><italic>I</italic><italic>I</italic><italic> </italic><italic>стадие</italic><italic>й (43,6 ± 13,2 года), 15 – с </italic><italic>III</italic><italic>–</italic><italic>I</italic><italic>V</italic><italic> </italic><italic>стадиям</italic><italic>и (46,9 ±</italic></p><p><italic>11,</italic><italic>1 года) РШМ. Были выделены 2 контрольные группы: в 1-ю вошли 30 практически здоровых доноров без патологии шейки матки и вируса папилломы человека (ВПЧ), во 2-ю – 30 больных преинвазивным и микроинвазивным РШМ. Установлено, что по мере прогрессии РШМ происходит повышение мембранной экспрессии </italic><italic>CD</italic><italic>9</italic><italic>5 </italic><italic>в МНПК-фракции при ЦИН </italic><italic>II</italic><italic>I</italic><italic> </italic><italic>степен</italic><italic>и и ранних стадиях РШМ более чем в 2 раза и наблюдается положительная корреляция количества </italic><italic>CD</italic><italic>95+-лимфоцито</italic><italic>в со стадией РШМ (</italic><italic>r</italic><italic> </italic><italic>= 0,91; </italic><italic>R</italic><italic>2 </italic><italic>= 0,82; </italic><italic>p</italic><italic> </italic><italic>&lt;</italic><italic>&lt; </italic><italic>0,01)</italic><italic>. Обнаружено усиление активности каспазы-8 (</italic><italic>r</italic><italic> </italic><italic>= 0,92; </italic><italic>R</italic><italic>2 </italic><italic>= 0,86; </italic><italic>p</italic><italic> </italic><italic>&lt;</italic><italic>&lt; </italic><italic>0,01)</italic><italic>, каспазы-6 (</italic><italic>r</italic><italic> </italic><italic>= 0,77; </italic><italic>R</italic><italic>2 </italic><italic>= 0,59; </italic><italic>p</italic><italic> </italic><italic>&lt;</italic><italic>&lt; </italic><italic>0,01) </italic><italic>и подавление активности каспазы-9 (</italic><italic>r</italic><italic> </italic><italic>= –0,60; </italic><italic>R</italic><italic>2 </italic><italic>= 0,36; </italic><italic>p</italic><italic> </italic><italic>&lt; 0,01) в МНПК, указывающие на повышение чувствительности к </italic><italic>F</italic><italic>a</italic><italic>s</italic><italic>- </italic><italic>индуцированном</italic><italic>у апоптозу. Напротив, в ткани опухоли, начиная с ЦИН </italic><italic>II</italic><italic>I</italic><italic> </italic><italic>степени</italic><italic>, формируется апоптоз-резистентный фенотип, что определено с помощью экспрессии каспазы-3 (</italic><italic>r</italic><italic> </italic><italic>= –0,72; </italic><italic>R</italic><italic>2 </italic><italic>= 0,52; </italic><italic>p</italic><italic> </italic><italic>&lt; 0,01), каспазы-6 (</italic><italic>r</italic><italic> </italic><italic>= –0,59; </italic><italic>R</italic><italic>2 </italic><italic>= 0,38; </italic><italic>p</italic><italic> </italic><italic>&lt; 0,01) и каспазы-9 (</italic><italic>r</italic><italic> </italic><italic>= –0,67; </italic><italic>R</italic><italic>2 </italic><italic>= 0,45; </italic><italic>p</italic><italic> </italic><italic>&lt; </italic><italic>0,01</italic><italic>) по уровню мРНК и протеолитической активности. Показано, что развитие РШМ сопровождается многосторонними нарушениями апоптотических процессов, которые реализуются в подавлении функционирования каспаз и множественной резистентности опухолевых клеток к апоптотическим стимулам. Полученные результаты дают возможность рассматривать гены каспазы как возможные перспективные биомаркеры в комплексной диагностике ЦИН и ранних форм РШМ (в сочетании с морфологическими критериями и другими молекулярными маркерами вирусного происхождения).</italic></p><p> </p></trans-abstract><kwd-group xml:lang="en"><kwd>cervical cancer</kwd><kwd>early diagnoses</kwd><kwd>caspases-3</kwd><kwd>-6</kwd><kwd>-8</kwd><kwd>-9 expression activity</kwd><kwd>apoptosis-resistant phenotype</kwd><kwd>Fas-induced</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>рак шейки матки</kwd><kwd>ранняя диагностика</kwd><kwd>экспрессия активности каспаз-3</kwd><kwd>-6</kwd><kwd>-8</kwd><kwd>-9</kwd><kwd>апоптоз-резистентный фенотип</kwd><kwd>Fas-индуцированный апоптоз</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Бахидзе Е.В., Лавринович О.Е., Чепик О.Ф., Киселев О.И. Роль вируса папилломы че- ловека в лимфогенном метастазировании плоскоклеточного рака шейки матки. Вопросы онкологии 2011;57(3):318–21. [Bakhidze E.V., Lavrinovich O.E., Chepik O.F., Kiselev O.I. The role of human papilloma virus in lymphatic cancer spread of squamous cell cancer of the cervix uteri. Voprosy onkologii = Issues in Oncology 2011;57(3):318–21. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Бахидзе Е.В., Лавринович О.Е., Чепик О.Ф., Киселев О.И. Роль вируса папилломы че- ловека в лимфогенном метастазировании плоскоклеточного рака шейки матки. Вопросы онкологии 2011;57(3):318–21. [Bakhidze E.V., Lavrinovich O.E., Chepik O.F., Kiselev O.I. The role of human papilloma virus in lymphatic cancer spread of squamous cell cancer of the cervix uteri. Voprosy onkologii = Issues in Oncology 2011;57(3):318–21. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Кадагидзе З.Г., Черткова А.И., Славина Е.Г. и др. Фенотип иммунокомпетентных кле- ток и его значение в противоопухолевом иммунном ответе. Вестник РАМН 2011;12:20–5. [Kadagidze Z.G., Chertkova A.I., Slavina E.G. et al. Phenotype of immunocompetent cells and its importance in anti-tumor immune response. Vestnik RAMN = Bulletin of Russian Academy of Medical Sciences 2011;12:20–5. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Кадагидзе З.Г., Черткова А.И., Славина Е.Г. и др. Фенотип иммунокомпетентных кле- ток и его значение в противоопухолевом иммунном ответе. Вестник РАМН 2011;12:20–5. [Kadagidze Z.G., Chertkova A.I., Slavina E.G. et al. Phenotype of immunocompetent cells and its importance in anti-tumor immune response. Vestnik RAMN = Bulletin of Russian Academy of Medical Sciences 2011;12:20–5. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Jayshree R.S., Sreenivas A., Tessy M., Krishna S. Cell intrinsic and extrinsic factors in cervical carcinogenesis. Indian J Med Res 2009;130(3):286–95.</mixed-citation><mixed-citation xml:lang="ru">Jayshree R.S., Sreenivas A., Tessy M., Krishna S. Cell intrinsic and extrinsic factors in cervical carcinogenesis. Indian J Med Res 2009;130(3):286–95.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Du J., Chen G.G., Vlantis A.C. et al. Resistance to apoptosis of HPV 16-infected laryngeal cancer cells is associated with decreased Bak and increased Bcl-2 expression. Cancer Lett 2004;205(1):81–8.</mixed-citation><mixed-citation xml:lang="ru">Du J., Chen G.G., Vlantis A.C. et al. Resistance to apoptosis of HPV 16-infected laryngeal cancer cells is associated with decreased Bak and increased Bcl-2 expression. Cancer Lett 2004;205(1):81–8.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Tungteakkhun S.S., Filippova M., Fodor N., Duerksen-Hughes P.J. The full-length isoform of human papillomavirus 16 E6 and its splice variant E6* bind to different sites on the procaspase 8 death effector domain. J Virol 2010;84(3):1453–63.</mixed-citation><mixed-citation xml:lang="ru">Tungteakkhun S.S., Filippova M., Fodor N., Duerksen-Hughes P.J. The full-length isoform of human papillomavirus 16 E6 and its splice variant E6* bind to different sites on the procaspase 8 death effector domain. J Virol 2010;84(3):1453–63.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Krammer P.H., Arnold R., Lavrik I.N. Life and death in peripheral T cells. Nat Rev Immunol 2007;7(7):532–42.</mixed-citation><mixed-citation xml:lang="ru">Krammer P.H., Arnold R., Lavrik I.N. Life and death in peripheral T cells. Nat Rev Immunol 2007;7(7):532–42.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Olsson M., Zhivotovsky B. Caspases and cancer. Cell Death Differ 2011;18(9):1441–9.</mixed-citation><mixed-citation xml:lang="ru">Olsson M., Zhivotovsky B. Caspases and cancer. Cell Death Differ 2011;18(9):1441–9.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Yuen M.F., Hughes R.D., Heneghan M.A. et al. Expression of Fas antigen (CD95) in peripheral blood lymphocytes and in liver- infiltrating, cytotoxic lymphocytes in patients with hepatocellular carcinoma. Cancer 2001;92(8):2136–41.</mixed-citation><mixed-citation xml:lang="ru">Yuen M.F., Hughes R.D., Heneghan M.A. et al. Expression of Fas antigen (CD95) in peripheral blood lymphocytes and in liver- infiltrating, cytotoxic lymphocytes in patients with hepatocellular carcinoma. Cancer 2001;92(8):2136–41.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9. Dworacki G., Meidenbauer N., Kuss I. et al. Decreased zeta chain expression and apoptosis in CD3+ peripheral blood T lymphocytes of patients with melanoma. Clin Cancer Res 2001;7(3 Suppl):947s–57s.</mixed-citation><mixed-citation xml:lang="ru">Dworacki G., Meidenbauer N., Kuss I. et al. Decreased zeta chain expression and apoptosis in CD3+ peripheral blood T lymphocytes of patients with melanoma. Clin Cancer Res 2001;7(3 Suppl):947s–57s.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10. Ma Y.X., Ye F., Chen H.Z. et al. Study of apoptosis and Fas expression of peritoneal fluid and peripheral blood T lymphocytes in patients with epithelial ovarian cancer and their relationship with CA125. Zhonghua Yi Xue Za Zhi 2007;87(11): 734–9.</mixed-citation><mixed-citation xml:lang="ru">Ma Y.X., Ye F., Chen H.Z. et al. Study of apoptosis and Fas expression of peritoneal fluid and peripheral blood T lymphocytes in patients with epithelial ovarian cancer and their relationship with CA125. Zhonghua Yi Xue Za Zhi 2007;87(11): 734–9.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11. Hoffmann T.K., Dworacki G., Tsukihiro T. et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 2002;8(8):2553–62.</mixed-citation><mixed-citation xml:lang="ru">Hoffmann T.K., Dworacki G., Tsukihiro T. et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 2002;8(8):2553–62.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12. Yoshikawa T., Saito H., Osaki T. et al. Elevated Fas expression is related to increased apoptosis of circulating CD8+ T cell in patients with gastric cancer. J Surg Res 2008;148(2):143–51.</mixed-citation><mixed-citation xml:lang="ru">Yoshikawa T., Saito H., Osaki T. et al. Elevated Fas expression is related to increased apoptosis of circulating CD8+ T cell in patients with gastric cancer. J Surg Res 2008;148(2):143–51.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">13. Hoser G., Wasilewska D., Domagała- Kulawik J. Expression of Fas receptor on peripheral blood lymphocytes from patients with non-small cell lung cancer. Folia Histochem Cytobiol 2004;42(4):249–52.</mixed-citation><mixed-citation xml:lang="ru">Hoser G., Wasilewska D., Domagała- Kulawik J. Expression of Fas receptor on peripheral blood lymphocytes from patients with non-small cell lung cancer. Folia Histochem Cytobiol 2004;42(4):249–52.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">14. Reesink-Peters N., Hougardy B.M., van den Heuvel F.A. et al. Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study. Gynecol Oncol 2005;96(3):705–13.</mixed-citation><mixed-citation xml:lang="ru">Reesink-Peters N., Hougardy B.M., van den Heuvel F.A. et al. Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study. Gynecol Oncol 2005;96(3):705–13.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">15. Aréchaga-Ocampo E., Pereira-Suárez A.L., del Moral-Hernández O. et al. HPV+ cervical carcinomas and cell lines display altered expression of caspases. Gynecol Oncol 2008;108(1):10–8.</mixed-citation><mixed-citation xml:lang="ru">Aréchaga-Ocampo E., Pereira-Suárez A.L., del Moral-Hernández O. et al. HPV+ cervical carcinomas and cell lines display altered expression of caspases. Gynecol Oncol 2008;108(1):10–8.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">16. Ekonomopoulou M.T., Babas E., Mioglou-Kalouptsi E. et al. Changes in activities of caspase-8 and caspase-9 in human cervical malignancy. Int J Gynecol Cancer 2011;21(3):435–8.</mixed-citation><mixed-citation xml:lang="ru">Ekonomopoulou M.T., Babas E., Mioglou-Kalouptsi E. et al. Changes in activities of caspase-8 and caspase-9 in human cervical malignancy. Int J Gynecol Cancer 2011;21(3):435–8.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">17. Wang W., Fang Y., Sima N. et al. Triggering of death receptor apoptotic signaling by human papillomavirus 16 E2 protein in cervical cancer cell lines is mediated by interaction with c- FLIP. Apoptosis 2011;16(1):55–66.</mixed-citation><mixed-citation xml:lang="ru">Wang W., Fang Y., Sima N. et al. Triggering of death receptor apoptotic signaling by human papillomavirus 16 E2 protein in cervical cancer cell lines is mediated by interaction with c- FLIP. Apoptosis 2011;16(1):55–66.</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">18. Jäger R., Zwacka R.M. The enigmatic roles of caspases in tumor development. Cancers 2010;2(4):1952–79.</mixed-citation><mixed-citation xml:lang="ru">Jäger R., Zwacka R.M. The enigmatic roles of caspases in tumor development. Cancers 2010;2(4):1952–79.</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">19. Ibrahim R., Frederickson H., Parr A. et al. Expression of FasL in squamous cell carcinomas of the cervix and cervical intraepithelial neoplasia and its role in tumor escape mechanism. Cancer 2006;106(5): 1065–77.</mixed-citation><mixed-citation xml:lang="ru">Ibrahim R., Frederickson H., Parr A. et al. Expression of FasL in squamous cell carcinomas of the cervix and cervical intraepithelial neoplasia and its role in tumor escape mechanism. Cancer 2006;106(5): 1065–77.</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">20. Patel S., Chiplunkar S. Host immune responses to cervical cancer. Curr Opin Obstet Gynecol 2009;21(1):54–9.</mixed-citation><mixed-citation xml:lang="ru">Patel S., Chiplunkar S. Host immune responses to cervical cancer. Curr Opin Obstet Gynecol 2009;21(1):54–9.</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">21. de Wilde J., De-Castro Arce J., Snijders P.J. et al. Alterations in AP-1 and AP-1 regulatory genes during HPV-induced carcinogenesis. Cell Oncol 2008;30(1):77–87.</mixed-citation><mixed-citation xml:lang="ru">de Wilde J., De-Castro Arce J., Snijders P.J. et al. Alterations in AP-1 and AP-1 regulatory genes during HPV-induced carcinogenesis. Cell Oncol 2008;30(1):77–87.</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">22. Jacobs J.F., Idema A.J., Bol K.F. et al. Prognostic significance and mechanism of Treg infiltration in human brain tumors. J Neuroimmunol 2010;225(1–2): 195–9.</mixed-citation><mixed-citation xml:lang="ru">Jacobs J.F., Idema A.J., Bol K.F. et al. Prognostic significance and mechanism of Treg infiltration in human brain tumors. J Neuroimmunol 2010;225(1–2): 195–9.</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">23. Würstle M.L., Laussmann M.A., Rehm M. The caspase-8 dimerization/dissociation balance is a highly potent regulator of caspase-8, -3, -6 signaling. J Biol Chem 2010;285(43):33209–18.</mixed-citation><mixed-citation xml:lang="ru">Würstle M.L., Laussmann M.A., Rehm M. The caspase-8 dimerization/dissociation balance is a highly potent regulator of caspase-8, -3, -6 signaling. J Biol Chem 2010;285(43):33209–18.</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">24. Zhou J.H., Chen H.Z., Ye F. et al. Fas- mediated pathway and apoptosis in normal cervix, cervical intraepithelial neoplasia and cervical squamous cancer. Oncol Rep 2006;16(2):307–11.</mixed-citation><mixed-citation xml:lang="ru">Zhou J.H., Chen H.Z., Ye F. et al. Fas- mediated pathway and apoptosis in normal cervix, cervical intraepithelial neoplasia and cervical squamous cancer. Oncol Rep 2006;16(2):307–11.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
